GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurological and autoimmune diseases, including multiple sclerosis (MS) and type 1 diabetes (T1D), today published an article on the new therapeutic approach for type-1 diabetes using GNbAC1, an anti-HERV-W-Env monoclonal antibody.
More information on :
